
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Prior authorization reform, AI deployment, GLP-1 management and specialty drug costs are among the issues reshaping payer and provider strategy this year.
Healthcare organizations entered 2026 facing continued financial pressure, rising specialty drug costs and growing demand for behavioral healthcare while also being pushed to modernize operations and improve access.






